Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- The 10 Weirdest Drug Stories of the Month
- Another page has been torn off the calendar, and that means it's time to open up Big Pharma's vault of peculiarities and do a roundup of strange-but-true tales from the world of drugs that surfaced on my radar last month. I give you the 10 weirdest drug...
- Blog posts 2008-10-01
Additional Resources
- Indevus Pharmaceuticals Scheduled to Present at BioCentury NewsMakers in the Biotech Industry Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that the Company will present at the NewsMakers in the Biotech Industry Conference in New York City on September 7, 2006 at 10:00 am. The presentation will be web cast live and may be accessed by visiting www.corporate-ir.net/ireye/conflobby.zhtml?ticker=IDEV&item_id=1376367 A link...
- Research articles 2006-08-31
- Indevus to Present at 2006 Pacific Growth Equities Life Sciences Growth Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it will present at the 2006 Pacific Growth Equities Life Sciences Growth Conference on Wednesday, June 14, 2006 at 10:30 AM pacific time. The presentation will be web cast live and may be accessed by visiting www.corporate-ir.net/ireye/confLobby.zhtml?ticker=IDEV&item_id=1315772 A link...
- Research articles 2006-06-08
- Indevus Pharmaceuticals Scheduled to Present at Wells Fargo Healthcare Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it will present at the Wells Fargo Securities HealthCare Conference on Tuesday, March 1, 2005 at 3:45 p.m. eastern time. The Company's presentation will be web cast live and may be accessed by visiting http://www.wsw.com/webcast/wfc/idev. A link to this...
- Research articles 2005-02-23
- Indevus Pharmaceuticals Scheduled to Present at UBS 2004 Global Life Sciences Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that its presentation at the UBS Global Life Sciences Conference on September 27, 2004 at 12:00 Noon will be web cast live and may be accessed by visiting http://www.ibb.ubs.com, clicking on the Conferences box and selecting the web cast link...
- Research articles 2004-09-20
- Indevus to Present at the UBS 2005 Global Life Sciences Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that Glenn L. Cooper, M.D., the Company's chairman, president and chief executive officer, will present at the UBS 2005 Global Life Sciences Conference on September 27, 2005 at 2:00 P.M. ET. The presentation will be web cast live and may...
- Research articles 2005-09-22
- Indevus Pharmaceuticals Scheduled to Present at the UBS Global Life Sciences Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that the Company will present at the UBS Global Life Sciences Conference in New York City on September 27, 2006 at 10:30 a.m. The presentation will be web cast live and may be accessed by visiting http://events.streamx.us/US/event/EventDetails.aspx?id=ubs20060925. A link to...
- Research articles 2006-09-20
- Logo for Indevus Pharmaceuticals, Inc. -Nasdaq: IDEV-
- Business Editors & Health/Medical Writers LEXINGTON, Mass.--BW HealthWire--April 5, 2002 The logo for Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) is now available on http://www.newstream.com. Indevus, formerly Interneuron Pharmaceuticals, Inc., began trading on the Nasdaq Stock Market on April 3, 2002. You can reach the Company's press release announcing...
- Research articles 2002-04-05
- Indevus Pharmaceuticals Inc. (Active Pharmaceutical Ingredient Watch).(Pfizer returns pagoclone rights)(Brief Article)
- INDEVUS Pharmaceuticals Inc. reports Pfizer Inc. will return exclusive, global development rights to the anxiety drug pagoclone. The results of Pfizer's most recent clinical trials with pagoclone did not achieve the level of efficacy established in INDEVUS Pharmaceuticals Inc. reports Pfizer Inc. will return...
- Research articles 2002-06-17
- Indevus Announces Licensing Agreement Related to Citicoline
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced a licensing agreement between Grupo Ferrer and IVAX Corporation for citicoline, an oral neuroprotective therapy for the treatment of stroke. Under the terms of this agreement, IVAX will be responsible for fulfilling the requirements for FDA approval of citicoline for...
- Research articles 2004-10-26
- Indevus Pharmaceuticals Scheduled to Present at Friedman Billings Ramsey 2006 Growth Investor Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that Glenn L. Cooper, M.D., chairman, president and chief executive officer, will present at the Friedman Billings Ramsey 2006 Growth Investor Conference in New York on May 31, 2006 at 8:15 a.m. eastern time. The presentation will be web cast...
- Research articles 2006-05-25
- Indevus to Present At UBS Global Specialty Pharmaceuticals Conference
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that Michael W. Rogers, executive vice president and chief financial officer of Indevus, is scheduled to make a presentation at the UBS Global Specialty Pharmaceuticals Conference. The conference will be held at The Grand Hyatt in New York City. Mr....
- Research articles 2006-04-19
- Indevus Pharmaceuticals Inc. F2Q08 (Qtr End 3/31/08) Earnings Call Transcript
- Earnings Call ExcerptIndevus Pharmaceuticals Inc. IDEV F2Q08 (Qtr End 3/31/08) Earnings Call April 30, 2008 9:00 am ET Executives Brooke Wagner - VP of Corporate Communications Michael Rogers - EVP and CFO Glenn Cooper - Chairman and CEO Analysts Gary Nachman - Leerink & Swann Juan Sanchez - Punk...
- Earnings calls 2008-05-13
- Indevus Files Shelf Registration Statement
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission ("SEC"). When declared effective by the SEC, the shelf registration statement will give Indevus the option to offer and sell up to 10...
- Research articles 2005-12-28
- Valera Pharmaceuticals, Inc. Announces Intention to Delist From NASDAQ Upon Consummation of the Proposed Merger With Indevus Pharmaceuticals, Inc.
- Valera Pharmaceuticals (NASDAQ: VLRX) today announced that it has submitted a request to the NASDAQ Stock Market, Inc. for withdrawal of its common stock from The Nasdaq Global Market following the closing of the proposed merger among Valera, Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), and a wholly owned subsidiary of Indevus....
- Research articles 2007-04-06
- Indevus Reports Interim Review of NEBIDO Phase III Data Indicates Trial Is Likely to Succeed.
- M2 PRESSWIRE-26 March 2007-News Flash: Indevus Reports Interim Review of NEBIDO Phase III Data Indicates Trial Is Likely to SucceedC1994-2007 M2 COMMUNICATIONS LTD RDATE:26032007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay...
- Research articles 2007-03-26
- Indevus Pharmaceuticals, Inc., Formerly Interneuron, to Begin Trading On Nasdaq
- Business Editors and Health/Medical Writers LEXINGTON, Mass.--BW HealthWire--April 2, 2002 Indevus Pharmaceuticals, Inc., formerly Interneuron Pharmaceuticals, Inc. (NASDAQ: IPIC), today announced that the Company will trade on the Nasdaq Stock Market under the new ticker symbol, IDEV, beginning tomorrow, April 3, 2002. Interneuron's shareholders approved the corporate name...
- Research articles 2002-04-02
- Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
- To: FOREIGN EDITORS Contact: Michael W. Rogers, Executive Vice President and CFO, +1- 781-861-8444, or Brooke D. Wagner, VP, Corp. Communications, +1-781- 402-3410, both of Indevus Pharmaceuticals, Inc. LEXINGTON, Mass., April 3, 2008 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced the signing of a License, Supply and...
- Research articles 2008-04-03
- Endo Pharmaceuticals to acquire Indevus Pharmaceuticals for $370 million
- An additional approximately $267 million, or $3 per Indevus share, in cash will be payable in the future upon achievement of certain regulatory and sales milestones. The transaction has been approved by the boards of directors of both companies. David Holveck, president and CEO of Endo, said: "This merger reflects...
- News items 2009-08-07
- Indevus Licenses U.S. Rights to NEBIDO® from Schering AG, Germany
- LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has licensed exclusive U.S. rights from Schering AG, Germany (NYSE: SHR) to market NEBIDOR, a long-acting injectable testosterone preparation for the treatment of male hypogonadism. NEBIDO, which was recently approved and launched in Europe, is the first injectable...
- Research articles 2005-07-29
- << Previous
- page 1 of 1
- Next >>
